- Product Detail
- Product Tags
- Buyer Reviews
We try for excellence, company the customers", hopes to be the best cooperation workforce and dominator enterprise for personnel, suppliers and clients, realizes value share and steady marketing for Imatinib Mesilate API IMatinib-D4,Imatinib Base Gleevec Pills,Imatinib Mesilate Intermediate. Welcome any inquiry to our firm. We will be happy to ascertain helpful business enterprise relationships along with you!
Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications).Product Name: Imatinib Mesilate
CAS NO: 220127-57-1
Standard: Enterprise Standard
Molecular Formula: C30H35N7O4S
Molecular Weight : 589.71
Description: White crystal or crystalline powder
Chemical names, synonyms:
4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate, STI-571, IMATINIB BASE(IMA-3), Imatinib (STI-571) Mesylate
Minimum purity: 99%
White to off-white Crystalline Powder
Identification By IR
IR spectrum of the sample should concordant to the standard spectrum.
Soluble in Water
NMT 0.5% w/w
Single Max. Imp : NMT 0.1 %
Total Max Imp : NMT 1.0 %
Assay (By HPLC)
NMT 98.0% And NLT 102 %
Imatinib Mesylate is a targeted therapy. Imatinib Mesylate is classified as a signal transduction inhibitor - protein-tyrosine kinase inhibitor.
A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.
Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.
"Having a sound business enterprise credit score, outstanding after-sales assistance and modern producing facilities, we have now earned an exceptional name among our shoppers across the planet for 20127-57-1 Mesilate cas 152459-95-5. The product will supply to all over the world, such as: North Korea,Comoros,Liechtenstein. With a team of experienced and knowledgeable personnel our market covers South America, the USA, the Mid East and North Africa. Many customers have become our friends after good cooperation with us. If you have the requirement for any of our products please contact us now. We are looking forward to hearing from you soon.
Email To This Supplier